http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112394178-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2570-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 |
| filingDate | 2020-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112394178-B |
| titleOfInvention | Biomarkers, kits and applications of moxifloxacin-related liver injury |
| abstract | The present invention discloses biomarkers of moxifloxacin-related liver injury, including L-tyrosine, L-leucine, L-valine, levodopa and L-isoleucine. The present invention also discloses a kit comprising reagents capable of detecting biomarkers. The invention also discloses the application of the biomarkers in the research of metabolomics, metabolic pathways and intestinal flora changes, or in the preparation of liver injury diagnostic kits or the research and development of diagnostic equipment. The biomarkers provided by the invention are easy to detect and have the functions of detection and early warning. The present invention is the first to report the metabolic changes and microbial composition differences of moxifloxacin-induced hepatotoxicity, and to correlate metabolomics with the intestinal flora on the gut-liver axis to study moxifloxacin-induced liver damage, butyrate deficiency causes The energy-related metabolic disorders and intestinal microbial dysbiosis cause liver damage, which will help to elucidate the pathogenesis of moxifloxacin-induced hepatotoxicity and improve people's understanding of drug-induced liver injury. |
| priorityDate | 2020-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 243.